THE US Food and Drug Administration has implemented a new policy to expedite the review of generic drug applications where competition is limited, along with a list of off-patent, off-exclusivity branded drugs without approved generics as part of its Drug Competition Action Plan.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jun 17